Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

Metastatic Breast Cancer Clinical Trial

Official title:

A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02418689
• Other study ID #: NOV120101-203
• Status: Completed
• Phase: Phase 2
• Start date: April 2015
• Est. completion date: April 2021

Study information

• Verified date: March 2021
• Source: Hanmi Pharmaceutical Company Limited
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), in HER2-overexpressed recurrent stage IV breast cancer patients who received at least 2 prior HER2-directed regimens.

Description:

To evaluate the efficacy of NOV120101 (Poziotinib) as a therapeutic agent for HER2-overexpressed recurrent stage IV breast cancer, patients who have received at least two prior HER2-directed regimens will be enrolled in this study. Subjects will receive NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by 1-week drug-free intervals between cycles until disease progression or unacceptable toxicity development. Progression Free Survival (PFS) will be analyzed as the primary endpoint in this trial. Secondary endpoints including PFS rate at 12 weeks, ORR, DCR, OS and TTP will also be analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: April 2021
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Who give agreement to the collection of tumor tissue specimen suitable for biomarker research

2. ECOG performance status = 2

3. Who received following treatments as Taxane-based chemotherapy and at least two HER2-targeted* therapy including Trastuzumab.

• lapatinib, T-DM1 (trastuzumab emtansine), pertuzumab

4. Adequate hematological, hepatic and renal functions

Exclusion Criteria:

1. Who received NOV120101 prior to participation in this study

2. Patients expected to exhibit hypersensitivity to IP or its components

3. Any other concurrent chemotherapies

4. Concurrent or prior radiotherapy within 4 weeks before study participation. However, patients with additional lesions other than the major lesion who completed and recovered from all treatment-related toxicities after radiotherapy in a limited area as a palliative therapy are allowed to participate in the study

5. History of symptomatic or unstable angina and congestive heart failure; arrhythmia requiring medications; or clinically significant myocardial infarction or other cardiac diseases within 6 months before study participation for which any related-significant risks are expected

6. Patients whose left ventricle ejection fraction (LVEF) is below the institutional lower limit of normal. However, if no lower limit of normal is defined in the site, the lower limit or normal is 50%.

7. Concurrent active hepatic or biliary disease (with exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver diseases)

8. History or concurrent ongoing/active infection, or uncontrolled diseases including, but not limited to, psychiatric illness/social situations which may limit the compliance with study procedures

9. Prior chemo-, immuno-, or surgical therapy within 3 weeks, or hormone therapy within 1 week before IP administration

10. History of primary malignancies other than breast cancer.

11. Patients with central nervous system (CNS) metastases.

12. Patients receiving or expected to receive bisphosphonate for prophylactic use without any bone-related diseases during the trial, for the exception of the treatment for bone metastases or osteoporosis initiated prior the IP administration.

13. Clinically significant or recent acute gastrointestinal disorders with diarrhea as a major symptom

14. Who are unstable or with unresolved severe adverse event(s)

15. Pregnancy or breast-feeding

16. Women of childbearing potential or men who are unwilling to use adequate contraception or be abstinent during the trial and for at least 2 months after the end of treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• NOV120101 (Poziotinib)
NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development

Locations

Country	Name	City	State
Korea, Republic of	Chungbuk National University Hospital	Cheongju-si	Chungcheongbuk-do
Korea, Republic of	Samsung Medical Center	Gangnam-gu	Seoul
Korea, Republic of	National Cancer Center	Goyang-si	Gyeonggi-do
Korea, Republic of	Seoul National University Hospital	Jongno-gu	Seoul
Korea, Republic of	Severance Hospital	Seodaemun-gu	Seoul
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam-si	Gyeonggi-do
Korea, Republic of	Asan Medical Center	Songpa-gu	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Hanmi Pharmaceutical Company Limited

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Population pharmacokinetics (PK) of NOV120101 (Poziotinib) - Ka, CL(clearance), Vd(volume of distribution)		4 weeks
Other	Number of Participants with Adverse Events as a Measure of Safety and Tolerability		2 years
Primary	Progression free survival (PFS)		By 12 months after enrollment of the last subject
Secondary	PFS rate at Week 12		12 weeks
Secondary	Objective Response Rate (ORR)	the proportion of patients with complete response (CR) and/or partial response (PR)	By 12 months after enrollment of the last subject
Secondary	Disease Control Rate (DCR)	the proportion of patients with CR, PR and/or stable disease (SD)] [Safety Issue?	By 12 months after enrollment of the last subject
Secondary	Duration of Disease Control		By 12 months after enrollment of the last subject
Secondary	Overall Survival (OS)		By 12 months after enrollment of the last subject
Secondary	Time To Progression (TTP)		By 12 months after enrollment of the last subject
Secondary	Time to objective response		By 12 months after enrollment of the last subject
Secondary	Duration of objective response		By 12 months after enrollment of the last subject